Bladder cancer: TICE, Connaught BCG yield similar RFS

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • No significant difference in recurrence-free survival (RFS) between TICE and Connaught Bacillus Calmette-Guerin (BCG) strains used in combination with interferon in BCG-naïve and BCG-failure patients with nonmuscle-invasive bladder cancer.

 

Why this matters

  • There has been limited investigation on substrain comparative efficacy, though differences in phenotypes and antigenicity have been reported.

Key results

  • BCG naïve patients who received TICE BCG had RFS rates of 80% at 3 mo, 64% at 1 y, and 54% at 2 y. 
  • Connaught BCG patients had RFS rates of 83%, 70%, and 65%, respectively. 
  • Univariable analysis found duration of disease >2 y (P=.04), multifocal tumors (P=.04), tumor size >5 cm vs <0.5 cm (P<0.01), and TICE BCG (P=.05) were associated with increased risk for recurrence. 
  • After controlling for duration of disease, tumor focality, and tumor size, strain was no longer an independent risk factor (P=.28). 
  • BCG-failure patients who received TICE BCG had 3-mo, 1-y, and 2-y RFS rates of 79%, 53%, and 44%, respectively. 
  • Connaught BCG patients had rates of 81%, 58%, and 47%, respectively. 
  • BCG strain had no significant prognostic value for recurrence (P=.53).

Study design

  • Post hoc analysis of a phase 2 study (N=901). 
  • Funding: None disclosed.

Limitations

  • Post hoc analysis. 
  • Nonrandomized.